{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:55:57Z","timestamp":1794059757097,"version":"4.8.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax (VEN) combined with hypomethylating agents is approved for frontline therapy in older\/unfit patients with acute myeloid leukemia (AML). However, prospective data on this low-intensity therapy in treatment-naive younger patients with AML are lacking. This study investigated the efficacy and safety of VEN plus decitabine (VEN-DEC) as induction in untreated young fit patients with AML in a randomized trial. Patients aged 18 to 59 years eligible for intensive chemotherapy were randomized 1:1 to receive VEN-DEC or IA-12 (idarubicin and cytarabine). All patients achieved composite complete remission (CRc) underwent high-dose cytarabine consolidation. The primary end point was CRc rate after induction. Of 255 screened, 188 were enrolled and randomly assigned, with 94 in each group. In the intention-to-treat population, CRc was 89% (84\/94) in the VEN-DEC group vs 79% (74\/94) in the IA-12 group (noninferiority P = .0021), with measurable residual disease negativity rates of 80% (67\/84) vs 76% (56\/74), respectively. VEN-DEC showed superior CRc in patients aged \u226540 years (91% vs 75%) and those with adverse risk (91% vs 42%) or epigenetic mutations (91% vs 67%), but lower CRc in RUNX1::RUNX1T1 fusion cases (44% vs 88%) than IA-12. Patients in the VEN-DEC group experienced fewer grade \u22653 infections (32% vs 67%) and shorter severe thrombocytopenia duration (median, 13 vs 19 days; P &amp;lt; .001). At a median follow-up of 12.1 months, overall and progression-free survival were similar between groups. In conclusion, VEN-DEC demonstrated noninferior response rates with superior safety over IA-12 in young patients with AML. The trial was registered at www.clinicaltrials.gov as #NCT05177731.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027217","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T12:18:28Z","timestamp":1740572308000},"page":"2645-2655","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0514-349X","authenticated-orcid":false,"given":"Jing","family":"Lu","sequence":"first","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4609-616X","authenticated-orcid":false,"given":"Sheng-li","family":"Xue","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8015-3546","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-feng","family":"He","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"},{"name":"2Department of Hematology, Soochow Hopes Hematonosis Hospital, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hui","family":"Hu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Canglang Hospital of Suzhou, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zai-xiang","family":"Tang","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-dan","family":"Xie","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fei","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-zhu","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-yao","family":"Shen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Du","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Soochow Hopes Hematonosis Hospital, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-xing","family":"Xue","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-ling","family":"Deng","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-qing","family":"Dou","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-ping","family":"Dai","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"De-pei","family":"Wu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-ning","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025052911213458100_bib1","unstructured":"Surveillance Research Program\n          . SEER\u2217Explorer: an interactive website for SEER cancer statistics. National Cancer Institute. Updated 5 November 2024. Accessed July 2024. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html."},{"issue":"20","key":"2025052911213458100_bib2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1200\/JCO.2011.38.9601","article-title":"Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia","volume":"30","author":"Tefferi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"2025052911213458100_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"2025052911213458100_bib4","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2025052911213458100_bib5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study","volume":"28","author":"Pautas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"2025052911213458100_bib6","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2025052911213458100_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"2025052911213458100_bib8","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/ajh.27434","article-title":"Frontline therapy of acute myeloid leukemia with lower intensity regimens: where are we now and where can we go?","volume":"99","author":"Marvin-Peek","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"2025052911213458100_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2025052911213458100_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"issue":"15","key":"2025052911213458100_bib11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025052911213458100_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"2025052911213458100_bib13","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1002\/ajh.26057","article-title":"Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia","volume":"96","author":"Arslan","year":"2021","journal-title":"Am J Hematol"},{"issue":"24","key":"2025052911213458100_bib14","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2025052911213458100_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41408-023-00948-x","article-title":"Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study","volume":"13","author":"Wang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"23","key":"2025052911213458100_bib16","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","article-title":"Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025052911213458100_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025052911213458100_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"issue":"7","key":"2025052911213458100_bib19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025052911213458100_bib20","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2025052911213458100_bib21","doi-asserted-by":"crossref","first-page":"E108","DOI":"10.1002\/ajh.26112","article-title":"Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive versus HMA \u00b1 venetoclax chemotherapy","volume":"96","author":"Begna","year":"2021","journal-title":"Am J Hematol"},{"issue":"19","key":"2025052911213458100_bib22","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025052911213458100_bib23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"2025052911213458100_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00432-024-05861-9","article-title":"Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia","volume":"150","author":"Yin","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2025052911213458100_bib25","first-page":"237","article-title":"Impact of AML1\/ETO fusion on the efficacy of venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia","volume":"19","author":"Jin","year":"2024","journal-title":"Target Oncol"},{"issue":"49","key":"2025052911213458100_bib26","doi-asserted-by":"crossref","first-page":"e2211429119","DOI":"10.1073\/pnas.2211429119","article-title":"Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia","volume":"119","author":"Cheng","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2025052911213458100_bib27","first-page":"3051","article-title":"The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults","volume":"4","author":"Banker","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025052911213458100_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-024-01042-6","article-title":"CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications","volume":"14","author":"Zhang","year":"2024","journal-title":"Blood Cancer J"},{"issue":"21","key":"2025052911213458100_bib29","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2025052911213458100_bib30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025052911213458100_bib31","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2025052911213458100_bib32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"}],"updated-by":[{"DOI":"10.1182\/blood.2026035742","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/22\/2645\/2376599\/blood_bld-2024-027217-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/22\/2645\/2376599\/blood_bld-2024-027217-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:21:46Z","timestamp":1748517706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/22\/2645\/535777\/Venetoclax-and-decitabine-vs-intensive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":32,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,5,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027217","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,29]]},"published":{"date-parts":[[2025,5,29]]}}}